Serina Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
Serina Therapeutics, Inc. (SER) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2026-03-25
- Serina Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2025-06-30 was $0.00.
- Serina Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2025-03-31 was $0.00.
- Serina Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-12-31 was -$14.00M.
- Serina Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2024 was -$7.00M, a 200.00% decline from fiscal 2023.
- Serina Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2023 was $7.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | -$14.00M derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | -$14.00M derived: sum of 3 quarters · filed 2026-03-25 | -$7.00M derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$14.00M derived: sum of 2 quarters · filed 2026-03-25 | -$7.00M derived: sum of 3 quarters · filed 2026-03-25 | -$14.00M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | -$14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$7.00M derived: sum of 2 quarters · filed 2026-03-25 | -$14.00M derived: sum of 3 quarters · filed 2026-03-25 | -$7.00M 10-K · filed 2026-03-25 |
| 2024-09-30 | $7.00M 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $7.00M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$7.00M 10-Q · filed 2025-08-11 | -$7.00M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$7.00M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $7.00M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |